Tanshinone IIA ameliorates non-alcoholic fatty liver disease through targeting peroxisome proliferator-activated receptor gamma and toll-like receptor 4

J Int Med Res. 2019 Oct;47(10):5239-5255. doi: 10.1177/0300060519859750. Epub 2019 Aug 5.

Abstract

Objective: To investigate the cellular mechanisms of action of tanshinone IIA on the fatty liver disease induced by a high-fat diet in an animal model of non-alcoholic fatty liver disease (NAFLD).

Methods: Adult male Sprague Dawley rats were randomized into one of three groups: regular rat diet (CON group) for 4 months; high-fat diet (HFD group) for 4 months; HFD for 2 months followed by tanshinone IIA treatment plus HFD (TAN group) for a further 2 months. A range of physical and biochemical markers of lipid accumulation and fatty liver disease were measured and compared between the groups.

Results: Tanshinone IIA treatment significantly reduced fat accumulation in the liver and plasma lipid levels that had been increased by HFD. The toll-like receptor (TLR4)/nuclear factor kappa B (NF-κB) signalling pathway was silenced by tanshinone IIA treatment. Tumour necrosis factor-α and interleukin-6 were reduced by tanshinone IIA. Hepatocyte apoptosis was inhibited by tanshinone IIA. Tanshinone IIA upregulated peroxisome proliferator-activated receptor gamma (PPAR-γ), which resulted in an improvement in the oxidative status.

Conclusion: Tanshinone IIA ameliorates NAFLD by targeting PPAR-γ and TLR4, resulting in decreased plasma lipids and oxidative stress, suggesting this strategy may form the basis of novel NAFLD therapies.

Keywords: Tanshinone IIA; inflammation; non-alcoholic fatty liver disease; oxidative stress; peroxisome proliferator-activated receptor gamma; toll-like receptor 4.

MeSH terms

  • Abietanes / pharmacology
  • Abietanes / therapeutic use*
  • Animals
  • Body Weight / drug effects
  • Lipids / blood
  • Liver / drug effects
  • Liver / enzymology
  • Liver / pathology
  • Male
  • Malondialdehyde / blood
  • Malondialdehyde / metabolism
  • NF-kappa B / metabolism
  • Non-alcoholic Fatty Liver Disease / drug therapy*
  • Non-alcoholic Fatty Liver Disease / genetics
  • Non-alcoholic Fatty Liver Disease / metabolism*
  • Organ Size / drug effects
  • Oxidation-Reduction
  • PPAR gamma / genetics
  • PPAR gamma / metabolism*
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Rats, Sprague-Dawley
  • Toll-Like Receptor 4 / genetics
  • Toll-Like Receptor 4 / metabolism*

Substances

  • Abietanes
  • Lipids
  • NF-kappa B
  • PPAR gamma
  • RNA, Messenger
  • Toll-Like Receptor 4
  • tanshinone
  • Malondialdehyde